Heart failure and diabetes mellitus: insight into comorbidity

Diabetes mellitus (DM) and heart failure (HF) are frequent comorbidities with a bidirectional relationship. Patients with HF have increased risk of developing DM, and those with DM are at greater risk of developing HF. HF does not fit clearly into the microangiopathy and macroangiopathy groups. It i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nina A. Petunina, Ivan V. Trukhin, Liubov V. Trukhina, Zhanna M. Sizova, Valeria L. Zakharova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2019
Materias:	diabetes mellitus heart failure diabetic cardiomyopathy comorbidity Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/676cc3c6b1e94ee5b0b38a3d85ae121a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:676cc3c6b1e94ee5b0b38a3d85ae121a
record_format	dspace
spelling	oai:doaj.org-article:676cc3c6b1e94ee5b0b38a3d85ae121a2021-11-14T09:00:22ZHeart failure and diabetes mellitus: insight into comorbidity2072-03512072-037810.14341/DM9784https://doaj.org/article/676cc3c6b1e94ee5b0b38a3d85ae121a2019-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9784https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Diabetes mellitus (DM) and heart failure (HF) are frequent comorbidities with a bidirectional relationship. Patients with HF have increased risk of developing DM, and those with DM are at greater risk of developing HF. HF does not fit clearly into the microangiopathy and macroangiopathy groups. It is known that coronary artery disease and arterial hypertension are the major causes of HF; however, it has been shown that DM can trigger functional and structural abnormalities in the myocardium via diabetic cardiomyopathy, a condition with either restrictive or dilated phenotype. While HF treatment is equally effective and safe in patients with and without DM, this statement is not applicable for antidiabetic treatment. Several antidiabetic drugs, such as rosiglitazone, pioglitazone and saxagliptin increase the risk of hospitalisation for HF, therefore these antidiabetic drugs are contraindicated in patients with DM and HF or patients at risk of developing HF. Despite a large number of clinical evidence, uncertainty about the safety of antidiabetic drugs in patients with HF always exists. In this review, the issues of DM treatment in patients with HF are addressed in detail.Nina A. PetuninaIvan V. TrukhinLiubov V. TrukhinaZhanna M. SizovaValeria L. ZakharovaEndocrinology Research Centrearticlediabetes mellitusheart failurediabetic cardiomyopathycomorbidityNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 22, Iss 1, Pp 79-87 (2019)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus heart failure diabetic cardiomyopathy comorbidity Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus heart failure diabetic cardiomyopathy comorbidity Nutritional diseases. Deficiency diseases RC620-627 Nina A. Petunina Ivan V. Trukhin Liubov V. Trukhina Zhanna M. Sizova Valeria L. Zakharova Heart failure and diabetes mellitus: insight into comorbidity
description	Diabetes mellitus (DM) and heart failure (HF) are frequent comorbidities with a bidirectional relationship. Patients with HF have increased risk of developing DM, and those with DM are at greater risk of developing HF. HF does not fit clearly into the microangiopathy and macroangiopathy groups. It is known that coronary artery disease and arterial hypertension are the major causes of HF; however, it has been shown that DM can trigger functional and structural abnormalities in the myocardium via diabetic cardiomyopathy, a condition with either restrictive or dilated phenotype. While HF treatment is equally effective and safe in patients with and without DM, this statement is not applicable for antidiabetic treatment. Several antidiabetic drugs, such as rosiglitazone, pioglitazone and saxagliptin increase the risk of hospitalisation for HF, therefore these antidiabetic drugs are contraindicated in patients with DM and HF or patients at risk of developing HF. Despite a large number of clinical evidence, uncertainty about the safety of antidiabetic drugs in patients with HF always exists. In this review, the issues of DM treatment in patients with HF are addressed in detail.
format	article
author	Nina A. Petunina Ivan V. Trukhin Liubov V. Trukhina Zhanna M. Sizova Valeria L. Zakharova
author_facet	Nina A. Petunina Ivan V. Trukhin Liubov V. Trukhina Zhanna M. Sizova Valeria L. Zakharova
author_sort	Nina A. Petunina
title	Heart failure and diabetes mellitus: insight into comorbidity
title_short	Heart failure and diabetes mellitus: insight into comorbidity
title_full	Heart failure and diabetes mellitus: insight into comorbidity
title_fullStr	Heart failure and diabetes mellitus: insight into comorbidity
title_full_unstemmed	Heart failure and diabetes mellitus: insight into comorbidity
title_sort	heart failure and diabetes mellitus: insight into comorbidity
publisher	Endocrinology Research Centre
publishDate	2019
url	https://doaj.org/article/676cc3c6b1e94ee5b0b38a3d85ae121a
work_keys_str_mv	AT ninaapetunina heartfailureanddiabetesmellitusinsightintocomorbidity AT ivanvtrukhin heartfailureanddiabetesmellitusinsightintocomorbidity AT liubovvtrukhina heartfailureanddiabetesmellitusinsightintocomorbidity AT zhannamsizova heartfailureanddiabetesmellitusinsightintocomorbidity AT valerialzakharova heartfailureanddiabetesmellitusinsightintocomorbidity
_version_	1718429533678338048

Heart failure and diabetes mellitus: insight into comorbidity

Ejemplares similares